The total number of records retrieved from this search are 14. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_1145	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for gamma 34.5, lacZ and alpha 47 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice model isograft for TRAMP-C2 cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor growth after repated dose of virus for 4 days	Mode of deliveryIntraneoplastically	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID16278413
IDOV_1147	Virus nameHerpes simplex virus	Virus strainMutant	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationMutant for gamma 34.5, lacZ and alpha 47 gene	Virus aloneNo	Virus in combination with drug/radiationVirus strain in combination with androgen ablation therapy	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice model isograft for TRAMP-C2 cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume as compared to castration	Mode of deliverySubcutaneous	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMID16278413
IDOV_1840	Virus nameVesicular stomatitis virus	Virus strainMutant	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing SV5-F gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mic, injected for TRAMP-C2 cell line	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume after 30 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cells	Immunogenic effectNA	Clinical trialNA	PMID20172545
IDOV_1841	Virus nameVesicular stomatitis virus	Virus strainMutant	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing GFP protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mic, injected for TRAMP-C2 cell line	In-vivo virus concentration2.0E+7 pfu	In-vivo toxicityNA	In-vivo resultReduction in tumor volume after 42 days	Mode of deliveryIntratumoral	Pathway inducedVirus induce apoptosis in cancer cells	Immunogenic effectNA	Clinical trialNA	PMID20172545
IDOV_4395	Virus nameVesicular stomatitis virus	Virus strainMutant	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing HIF2alpha, Sox10 and c-Myc gene	Virus aloneNo	Virus in combination with drug/radiationVSV-HIF2alpha+ VSV-sox10+ VSV-cMYC	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice xenograft for GL261 cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo result60% mice survived on day 30, 20% mice survived on day 45 and last mice survived on day 60	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectAntiPD-1 antibody enhances the IL-17 and IFN-gamma production	Clinical trialNA	PMID26409567
IDOV_4396	Virus nameVesicular stomatitis virus	Virus strainMutant	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing HIF2alpha, Sox10 and GFP gene	Virus aloneNo	Virus in combination with drug/radiationVSV-HIF2alpha+ VSV-sox10+ VSV-GFP	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice xenograft for GL261 cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultAll mice survived upto day 30 fter that all was dead	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectAntiPD-1 antibody enhances the IL-17 and IFN-gamma production	Clinical trialNA	PMID26409567
IDOV_4397	Virus nameVesicular stomatitis virus	Virus strainMutant	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing N-Ras, cytC and TYRP-1 gene	Virus aloneNo	Virus in combination with drug/radiationVSV-N-Ras+VSV-cytC+ VSV-TYRP-1	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice xenograft for GL261 cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultAll mice survived upto day 10 fter that all was dead	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectAntiPD-1 antibody enhances the IL-17 and IFN-gamma production	Clinical trialNA	PMID26409567
IDOV_4398	Virus nameVesicular stomatitis virus	Virus strainMutant	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing HIF2alpha, Sox10 and c-Myc gene	Virus aloneNo	Virus in combination with drug/radiationVSV-HIF2alpha, VSV-Sox10+ VSV-cMyc+antiPD1	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice xenograft for GL261 cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultMice survived upto day 45	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectAntiPD-1 antibody enhances the IL-17 and IFN-gamma production	Clinical trialNA	PMID26409567
IDOV_4399	Virus nameVesicular stomatitis virus	Virus strainMutant	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationVirus expressing HIF2alpha, Sox10 and c-Myc gene	Virus aloneNo	Virus in combination with drug/radiationVSV-HIF2alpha, VSV-Sox10+ VSV-cMyc+IgG	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice xenograft for GL261 cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultMice survived upto day 35	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectAntiPD-1 antibody enhances the IL-17 and IFN-gamma production	Clinical trialNA	PMID26409567
IDOV_4400	Virus nameVesicular stomatitis virus	Virus strainMutant	Virus genome typeRNA	Virus familyRhabdoviridae	Virus genome modificationvirus expressing GFP	Virus aloneNo	Virus in combination with drug/radiationVSV-GFp+anti-GFP	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice xenograft for GL261 cell line	In-vivo virus concentration5.0E+6 pfu	In-vivo toxicityNA	In-vivo resultMice survived upto day 12	Mode of deliveryIntravenous	Pathway inducedNA	Immunogenic effectAntiPD-1 antibody enhances the IL-17 and IFN-gamma production	Clinical trialNA	PMID26409567
IDOV_5124	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-hDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of human DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing human DAI gene	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice xenograft for B16-OVA (1.0E+5 cells)	In-vivo virus concentration3.0E+6 on day 0 and 1.0E+6 on day 2	In-vivo toxicityNA	In-vivo resultReduction in tumor volume to 100 cubic mm compared to control 500 cubic mm after 12 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5125	Virus nameVaccinia virus	Virus strainvvdd-tdTomato-mDAI	Virus genome typeDNA	Virus familyPoxviridae	Virus genome modificationDeletion of tk gene and vaccinia growth gene and addition of murine DAI	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeVirus expressing murine DAI gene	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice xenograft for B16-OVA (1.0E+5 cells)	In-vivo virus concentration3.0E+6 on day 0 and 1.0E+6 on day 2	In-vivo toxicityNA	In-vivo resultComplete reduction in tumor volumecompared to control 500 cubic mm after 12 days	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectInduction of Immunogenic gene such as T cell activation	Clinical trialNA	PMID27626058
IDOV_5677	Virus nameHerpes simplex virus	Virus strainHSV-R8306	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5 gene and addition of IL-4 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice xenograft for GL-261 (1.0E+5)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultIncrease in survival of mice up to 28 day	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS7744899
IDOV_5678	Virus nameHerpes simplex virus	Virus strainHSV-R8306	Virus genome typeDNA	Virus familyHerpesviridae	Virus genome modificationDeletion mutant for Gamma 34.5 gene and addition of IL-10 gene	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineNA	Origin of cell lineNA	Cell lineNA	Concentration of cell lineNA	In-vitro toxicityNA	AssayNA	In-vitro virus concentrationNA	In-vitro resultNA	Model organismC57BL/6 mice xenograft for GL-261 (1.0E+5)	In-vivo virus concentration1.0E+6 pfu	In-vivo toxicityNA	In-vivo resultIncrease in survival of mice up to 26 day	Mode of deliveryIntratumoral	Pathway inducedNA	Immunogenic effectNA	Clinical trialNA	PMIDUS7744899